English, Article edition: Cost Effectiveness of Fluticasone Propionate Plus Salmeterol Versus Fluticasone Propionate Plus Montelukast in the Treatment of Persistent Asthma Richard D. OConnor; Harold Nelson; Rohit Borker; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119743
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Fluticasone Propionate Plus Salmeterol Versus Fluticasone Propionate Plus Montelukast in the Treatment of Persistent Asthma
Author
  • Richard D. OConnor
  • Harold Nelson
  • Rohit Borker
  • Amanda Emmett
  • Priti Jhingran
  • Kathleen Rickard
  • Paul Dorinsky
Physical Description
  • article
Notes
  • Background: Asthma is a chronic disease, the two main components of which are inflammation and bronchoconstriction. Fluticasone propionate (FP) and salmeterol, a strategy that treats both main components of asthma, has been recently compared with FP plus montelukast in a randomised clinical trial. The present study reports economic evaluation of these two strategies. Objective: To determine the relative cost effectiveness when persistent asthma is treated with FP/​salmeterol 100/​50mug twice daily administered via a single Diskus(R) inhaler device versus treatment with FP 100mug twice daily via a Diskus(R) inhaler plus oral montelukast 10mg once daily. Study design: A cost-effectiveness analysis was performed by applying cost unit data to resource utilisation data collected prospectively during a US randomised, double-blind, 12-week trial of FP/​salmeterol Patients and methods: Efficacy measurements in this analysis included improvement in forced expiratory volume in 1 second (FEV1) and symptom-free days. Direct costs included those related to study drugs, emergency room department visits, unscheduled physician visits, treatment of drug-related adverse events (oral candidiasis), and rescue medication (salbutamol [albuterol]). The study assumed a US third-party payer Results: Treatment with FP/​salmeterol resulted in a significantly higher proportion (p Conclusion: From a US third-party payer
  • Antiasthmatics, Asthma, Cost-effectiveness, Fluticasone-propionate, Montelukast, Salmeterol/​fluticasone-propionate
  • RePEc:wkh:phecon:v:22:y:2004:i:12:p:815-825
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment